Response to tipifarnib in all patients and by disease type
| Disease type . | n (%) . | CR, n (%) . | PR, n (%) . | ORR, (%) (95% CI) . | Median DR (95% CI) . | Median TTP (95% CI) . | Median OS (95% CI) . |
|---|---|---|---|---|---|---|---|
| All patients | 93 | 6 (7) | 13 (14) | 20 (13-30) | 7.5 (4.9-18.5) | 3.6 (2.1-4.5) | 14.8 (7.6-17.8) |
| Aggressive B-cell lymphoma group | 42 | 0 | 7 (17) | 17 (7-31) | 11.3 (4.9-17.1) | 2.8 (1.7-4.2) | 6.4 (4.1-10.7) |
| DLBCL | 37 (88) | 0 | 7 (19) | 19 | — | — | — |
| MCL | 4 (10) | 0 | 0 | 0 | — | — | — |
| FL III | 1 (2) | 0 | 0 | 0 | — | — | — |
| Indolent B-cell lymphoma group | 15 | 0 | 1 (7) | 7 (0.2-32) | 2 (NR) | 5.2 (4-9.2) | 20.6 (NR) |
| Chronic lymphocytic leukemia/small lymphocytic lymphoma | 5 (33) | 0 | 0 | 0 | — | — | — |
| Extranodal marginal zone | 1 (7) | 0 | 0 | 0 | — | — | — |
| FL grade I | 3 (20) | 0 | 0 | 0 | — | — | — |
| FL grade II | 6 (40) | 0 | 1 | 17 | — | — | — |
| HL/T group | 36 | 6 (17) | 5 (14) | 31 (16-48) | 7.5 (3.2-29.8) | 3.2 (1.9-5.8) | 19.7 (9-60) |
| HL | 19 (53) | 2 (11) | 2 (11) | 21 | — | — | — |
| Mycosis fungoides | 4 (11) | 0 | 2 (50) | 50 | — | — | — |
| Peripheral T-cell, unspecified | 8 (22) | 3 (38) | 1 (13) | 50 | — | — | — |
| Anaplastic large cell, cutaneous | 3 (8) | 1 (33) | 0 | 33 | — | — | — |
| Anaplastic large cell, systemic | 2 (6) | 0 | 0 | 0 | — | — | — |
| Disease type . | n (%) . | CR, n (%) . | PR, n (%) . | ORR, (%) (95% CI) . | Median DR (95% CI) . | Median TTP (95% CI) . | Median OS (95% CI) . |
|---|---|---|---|---|---|---|---|
| All patients | 93 | 6 (7) | 13 (14) | 20 (13-30) | 7.5 (4.9-18.5) | 3.6 (2.1-4.5) | 14.8 (7.6-17.8) |
| Aggressive B-cell lymphoma group | 42 | 0 | 7 (17) | 17 (7-31) | 11.3 (4.9-17.1) | 2.8 (1.7-4.2) | 6.4 (4.1-10.7) |
| DLBCL | 37 (88) | 0 | 7 (19) | 19 | — | — | — |
| MCL | 4 (10) | 0 | 0 | 0 | — | — | — |
| FL III | 1 (2) | 0 | 0 | 0 | — | — | — |
| Indolent B-cell lymphoma group | 15 | 0 | 1 (7) | 7 (0.2-32) | 2 (NR) | 5.2 (4-9.2) | 20.6 (NR) |
| Chronic lymphocytic leukemia/small lymphocytic lymphoma | 5 (33) | 0 | 0 | 0 | — | — | — |
| Extranodal marginal zone | 1 (7) | 0 | 0 | 0 | — | — | — |
| FL grade I | 3 (20) | 0 | 0 | 0 | — | — | — |
| FL grade II | 6 (40) | 0 | 1 | 17 | — | — | — |
| HL/T group | 36 | 6 (17) | 5 (14) | 31 (16-48) | 7.5 (3.2-29.8) | 3.2 (1.9-5.8) | 19.7 (9-60) |
| HL | 19 (53) | 2 (11) | 2 (11) | 21 | — | — | — |
| Mycosis fungoides | 4 (11) | 0 | 2 (50) | 50 | — | — | — |
| Peripheral T-cell, unspecified | 8 (22) | 3 (38) | 1 (13) | 50 | — | — | — |
| Anaplastic large cell, cutaneous | 3 (8) | 1 (33) | 0 | 33 | — | — | — |
| Anaplastic large cell, systemic | 2 (6) | 0 | 0 | 0 | — | — | — |
— indicates not applicable; and NR, not reported.